1 / 25

Emily Tanzler , MD Waseet Vance, MD

Stereotactic Ablative Radiation Therapy (SABR) for Early Stage Non-Small Cell Lung Cancer. Emily Tanzler , MD Waseet Vance, MD. Treatment Options for Early Stage Lung Cancer. Surgical Sub-Lobar Resection Lobectomy. Non-Surgical Conventional RT SBRT RFA.

Télécharger la présentation

Emily Tanzler , MD Waseet Vance, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Stereotactic Ablative Radiation Therapy (SABR) for Early Stage Non-Small Cell Lung Cancer Emily Tanzler, MD Waseet Vance, MD

  2. Treatment Options for Early Stage Lung Cancer Surgical • Sub-Lobar Resection • Lobectomy • Non-Surgical • Conventional RT • SBRT • RFA

  3. Clinical stage I NSCLC patients can be considered falling into three treatment groups: • Average-risk patients: typically treated with lobectomy • High-risk patients: typically treated with sublobar (segmental or wedge) resection • Medically inoperable patients: traditionally treated with external beam radiation therapy.

  4. Surgical resection is the gold standard for treatment of patients with stage I and II operable lung cancer • 5-year Overall Survival for stage I NSCLC • Clinical stage IA-61% • Pathologic stage IA-67% • Clinical stage IB-38% • Pathologic stage IB-57% (Mountain CF. Semin. Surg. Oncol. 18:106–115, 2000)

  5. Criteria for Resection • FEV1 • ACCP threshold for lobectomy: 1-1.5L • Recent series demonstrated increased complications for FEV1 <47% predicted • DLCO • > 60% Preoperative recommended • < 40% Predicted Post-Op Associated with high morbidity/mortality • Exercise Tolerance

  6. High Risk or “Marginally” Operable Patients • Substantial number (15-40%) of NSCLC patients present with impaired cardiopulmonary reserve • Increased risk of peri-operative complications and long-term disability with standard anatomic resections

  7. High Risk or “Marginally” Operable Patients • Will have difficulty during and after a lobectomy or pneumonectomy • Getting off ventilator • Getting out of hospital • Readmissions • Decreased vitality/quality of life post-resection

  8. Surgical Options – Lobectomy vs. Sublobar Resection T1N0 (Negative mediastinoscopy)

  9. Lobectomy vs. Sublobar Resection Sem Thor and CT Surg 2003 • LR ~10% with Lobectomy vs ~20-30% with sublobar resection

  10. Medically Inoperable • Observation alone in these patients is not a good option • In a study of 75 Stage I medically inoperable patients treated with observation alone • Lung cancer cause of death in 53% • Death from other comorbidities was 30% (McGarry, Chest 2002)

  11. Radiofrequency Ablation Placed percutaneously Electrode heated to 50 - 100° Coagulation Necrosis Treat tumor + margin Indications: Small (<3 cm) NSCLC or mets Complications: Pneumothorax (30%) Fever/Pleurisy/Effusions Radiology 2007

  12. Conventional Radiation Therapy IJROBP 1998 Local Control: 50 – 60%

  13. Stereotactic Ablative Radiation Therapy (SABR) is the emerging standard in the management of non-small cell lung cancer for the medically inoperable patient.

  14. Stereotactic Ablative Radiation Therapy (SABR) • Outpatient • Noninvasive/painless • No sedation or anesthesia required • Completed in 1-5 treatments • Entire course completed in 1-2 weeks • Each treatment only 20-60 minutes • No limitation in activities or recovery downtime • Spares significant lung tissue

  15. SABR vs Conventional RT • Local Control • Historic comparisons • SABR 54 Gy in 3 fx, 98% (local), 91% (lobe) (RTOG 0236) • EBRT 60-66 Gy / 30-33 fx, ~50% (Qiao, Lung Cancer 2003) • Beaumont experience comparing SABR vs EBRT (Lanni, Am J ClinOncol 2011) • SABR (48-60 Gy in 4-5 fx, n=45) vs. EBRT (70 Gy/35 fx, n=41) • 3y LC: 88% vs. 66% • Meta-analysis (Grutters, RadiotherOncol 2010) • SABR (n=895) vs. EBRT (n=1326) • 2y OS, 70% vs. 53% • 2y DFS, 83.4% vs. 67.4%

  16. Medically Inoperable: Peripheral Tumors- RTOG 0236 • Timmerman et al. JAMA. 2010 Mar 17;303(11):1070-6. • 55 patients with a median follow-up of 34.4 months • T1 tumors (44 patients) • T2 tumors (11 patients) • 3-year primary tumor control rate was 97.6% • 3-year rate of disseminated failure was 22.1%

  17. Medically Inoperable: Peripheral Tumors- RTOG 0236 • Disease-free survival at 3 years 48.3% • Overall survival at 3 years 55.8% • Median survival was 48.1 months • Toxicity • Grade 3 toxicity in 7 pts (12.7%); grade 4 in 2 pts (3.6%). No grade 5. • Rare rib fractures and dermatitis have been observed for chest wall tumors

  18. MEDICALLY OPERABLE PATIENTS • SABR data from Japan in operable patients who declined surgery • 87 patients with T1 (n=65) or T2 (n=22) tumors treated at 14 Japanese institutions • 5 year survivals for stage IA and IB comparable to surgery • Stage IA=77% • Stage IB=68% (Onishi, IJROBP 2010)

  19. MEDICALLY OPERABLE PATIENTS • 50 ptswwith T1 (n=24) or T2 (n=26) tumors treated with SABR from1994 to 1999. • 29 pts were medically operable but refused surgery • Entire cohort of 50 patients: • 3 year LC 94% • 3 year CSS 88% • 3 year OS 66% • Cohort of 29 operable patients • 3 year OS 86% (Uematsu, IJROBP 2001)

  20. MEDICALLY OPERABLE PATIENTS • 177 medically operable patients with T1 (60%) or T2 (40%) tumors treated with SABR from2003 to 2010 in the Netherlands • SABR dose of 60 Gy delivered in 3, 5, or 8 fractions using a risk adapted scheme • 3 year LC 93% • 3 year OS 84.7% (Lagerwaard, IJROBP 2012)

  21. Treatment Toxicities • Rates are generally low • > grade 3 pneumonitis, hypoxia: < 5% • Related to tumor location & fractionation schedule • Newer fractionation schemes and advanced treatment techniques have further improved toxicity profile

  22. SABR Case

  23. Treatment Response Timeline Initial Treatment 4 months Complete Radiographic Response 18 months No Evidence of Disease

  24. Conclusions • Surgery is the gold standard for operable patients • For inoperable or marginally operable high risk patients with Stage I lung cancer SABR offers excellent local control and similar survival to surgical approaches • Randomized trials have failed to accrue for various reasons- patients and physicians

  25. Thank You

More Related